The fas promoter polymorphism at position -670 is not associated with late-onset sporadic Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 17, Issue 3, 2004, Pages 143-146

  Rosenmann, Hanna ^a   Meiner, Zeev ^a   Kahana, Esther ^b   Aladjem, Zoja ^b   Friedman, Gideon ^a   Ben Yehuda, Arie ^a   Grenader, Tal ^a   Wertman, Eli ^c   Abramsky, Oded ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b BARZILAI MEDICAL CENTER   (Israel)

^c HERZOG HOSPITAL   (Israel)

Author keywords

Alzheimer's disease; Apoptosis; Fas; Polymorphism; TNFSRF6

Indexed keywords

APOLIPOPROTEIN E; FAS ANTIGEN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE LOCUS; HUMAN; JEW; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; ANTIGENS, CD95; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; ISRAEL; JEWS; MALE; MIDDLE AGED; PROMOTER REGIONS (GENETICS); RISK ASSESSMENT;

EID: 1542405251     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076347     Document Type: Article

References (20)

1. Pericak-Vance MA, Haines JL: Genetic susceptibility to Alzheimer disease. Trends Genet 1995;11:504-508.
2. Warwick Daw E, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsmand EM: The number of trait loci in lateonset Alzheimer disease. Am J Hum Genet 2000;66:196-204.
3. Tanzi RE, Bertram L: New frontiers in Alzheimer's disease genetics. Neuron 2001;32:181-184.
4. Smale G, Nichols NR, Brady DR, Finch CE, Horton WE: Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 1995;133:225-230.
5. Rosenmann H, Meiner Z, Kahana E, Aladjem Z, Friedman G, Ben-Yehuda A, Grenader T, Wertman E, Abramsky O: Association study of the codon 72 polymorphism in the pro-apoptotic gene p53 and Alzheimer's disease. Neurosci Lett, in press.
6. Nagata S: Apoptosis regulated by a death factor and its receptor: Fas ligand and Fas. Philos Trans R Soc Lond B Biol Sci 1994;345:281-287.
7. Nishimura T, Akiyama H, Yonehara S, Kondo H, Ikeda K, Kato M, Iseki E, Kosaka K: Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Res 1995;695:137-145.
8. Inazawa J, Iton N, Abe T, Nagata S: Assignment of the human Fas antigen gene (Fas) to 10q24.1. Genomics 1992;14:821-822.
9. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S, Yhu S, McInnis MG, Go RC, Vekrellis K, Selkoe DJ, Saunders AJ, Tanzi RE: Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000;290:2302-2303.
10. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM: Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000;290:2304-2305.
11. Feuk L, Prince JA, Breen G, Emahazion T, Carothers A, St Clair D, Brookes AJ: Apolipoprotein-E dependent role for the FAS receptor in early onset Alzheimer's disease: Finding of a positive association for a polymorphism in the TNFRSF6 gene. Hum Genet 2000;107:391-396.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
13. Cockrell JR, Folstein MF: Mini-Mental State Examination (MMSE). Psychopharmacol Bull 1988;24:689-692.
14. Huang QR, Morris D, Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582.
15. Chapman J, Estupinan J, Asherov A, Goldfarb LG: A simple and efficient method for apolipoprotein E genotype determination. Neurology 1996;46:1484-1485.
16. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, Rosner MR, Selkoe DJ: Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J Neurosci 2000;20:1657-1665.
17. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S: Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 2003;162:313-319.
18. Abraham R, Myers A, Wavrant-DeVrieze F, Hamshere ML, Thomas HV, Marshall H, Compton D, Spurlock G, Turic D, Hoogendoorn B, Kwon JM, Petersen RC, Tangalos E, Norton J, Morris JC, Bullock R, Liolitsa D, Lovestone S, Hardy J, Goate A, O'Donovan M, Williams J, Owen MJ, Jones L: Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease. Hum Genet 2001;109:646-652.
19. Boussaha M, Hannequin D, Verpillat P, Brice A, Frebourg T, Campion D: Polymorphisms of insulin-degrading enzyme gene are not associated with Alzheimer's disease. Neurosci Lett 2002 23;329:121-123.
20. Seo JC, Han SW, Yin CS, Koh HK, Kim CH, Kim EH, Leem KH, Lee HS, Park HJ, Kim SA, Choe BK, Lee HJ, Yim SV, Kim CJ, Chung JH: Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patients. Exp Mol Med 2002;34:294-298.